NCT04117958 is a Phase 1 clinical trial of AMG 199 in MUC17-positive Solid Tumors, sponsored by Amgen.

Who is sponsoring NCT04117958?

NCT04117958 is sponsored by Amgen.

What drugs are being tested in NCT04117958?

Interventions in NCT04117958: AMG 199.

What condition does NCT04117958 study?

NCT04117958 studies MUC17-positive Solid Tumors.

Is NCT04117958 still recruiting?

NCT04117958 is currently terminated. Last updated 14 October 2025.

Last reviewed 2025-10-14 · How we verify

NCT04117958

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

Terminated Phase 1 Last updated 14 October 2025

What this trial tests

Phase 1 trial testing AMG 199 in MUC17-positive Solid Tumors in 58 participants. Terminated before completion.

Timeline

20 January 2020

Primary endpoint
1 June 2023

1 June 2023

Quick facts

Lead sponsor	Amgen
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	20 January 2020
Primary completion	1 June 2023
Estimated completion	1 June 2023
Sites	21 locations across France, Japan, Netherlands, Austria, Taiwan, Germany, South Korea, United States

Drugs / interventions tested

AMG 199 — full drug profile →

Conditions studied

MUC17-positive Solid Tumors — all drugs for MUC17-positive Solid Tumors →

Sponsor

Amgen — full company profile →

Who can join

Adults 18 to 99, any sex, with MUC17-positive Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and tolerability of AMG 199 in adult subjects and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Signaling pathways and therapeutic interventions in gastric cancer.
Lei ZN, Teng QX, Tian Q, Chen W, et al · · 2022 · cited 220× · PMID 36209270 · DOI 10.1038/s41392-022-01190-w
The landscape of bispecific T cell engager in cancer treatment.
Zhou S, Liu M, Ren F, Meng X, et al · · 2021 · cited 172× · PMID 34039409 · DOI 10.1186/s40364-021-00294-9
Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J, Yang Y, Wang G, Liu M. · · 2022 · cited 127× · PMID 36389699 · DOI 10.3389/fimmu.2022.1035276
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors.
Middelburg J, Kemper K, Engelberts P, Labrijn AF, et al · · 2021 · cited 122× · PMID 33466732 · DOI 10.3390/cancers13020287
Overcoming the challenges associated with CD3+ T-cell redirection in cancer.
Singh A, Dees S, Grewal IS. · · 2021 · cited 82× · PMID 33469153 · DOI 10.1038/s41416-020-01225-5
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors.
Ouyang P, Wang L, Wu J, Tian Y, et al · · 2024 · cited 66× · PMID 38545114 · DOI 10.3389/fimmu.2024.1344272
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements.
Sun Y, Yu X, Wang X, Yuan K, et al · · 2023 · cited 62× · PMID 37719370 · DOI 10.1016/j.apsb.2023.05.023
Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy.
Lee DH, Choi S, Park Y, Jin HS. · · 2021 · cited 53× · PMID 34681277 · DOI 10.3390/ph14101053

Verify or expand the search:

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04117958 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 14 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04117958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing